Key Takeaways
- Jim Cramer cautioned against purchasing stocks experiencing “parabolic” surges, particularly in the tech and AI sectors, noting these rallies tend to reverse quickly
- He believes superior investment opportunities lie in undervalued, neglected stocks currently out of favor
- The CNBC Investing Club Charitable Trust purchased Johnson & Johnson during its decline
- Cramer named J&J as his top pharmaceutical stock pick, surpassing Eli Lilly, thanks to its robust drug pipeline and corporate restructuring
- He emphasized the importance of maintaining portfolio balance between trending and overlooked investments
During Monday’s episode of CNBC’s Mad Money, Jim Cramer delivered a clear message to investors: abandon the strategy of pursuing the market’s hottest performers and redirect attention toward overlooked opportunities.
Cramer characterized stocks experiencing “parabolic” trajectories—particularly within technology and artificial intelligence sectors—as risky purchases. He admitted that his own attempts to capitalize on such momentum plays have typically resulted in losses.
“Those are all too hot, hot, hot for me,” Cramer stated, referencing high-momentum semiconductor and AI stocks.
Rather than jumping on bandwagons like Intel or Advanced Micro Devices, Cramer revealed he’s taking a contrarian approach. He’s accumulating shares of high-quality companies that have declined and lost Wall Street’s attention.
His CNBC Investing Club Charitable Trust recently added Johnson & Johnson to its holdings during the stock’s descent. The healthcare sector currently ranks as the S&P 500’s poorest performer year-to-date.
“We are buying it in freefall,” Cramer explained. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Rationale for Johnson & Johnson
Cramer elevated Johnson & Johnson to his preferred pharmaceutical stock position, displacing Eli Lilly. He pointed to the company’s drug development pipeline and its strategic business transformation as key factors driving his conviction.
Johnson & Johnson has systematically divested underperforming business units while intensifying its focus on pharmaceutical innovation. The company boasts numerous drugs in advanced clinical trials along with several recent regulatory approvals.
According to Cramer, recent stock weakness stems primarily from external noise, especially litigation concerns surrounding talc products. He contends these worries have obscured the substantial operational improvements the company has achieved.
Cramer also identified a recurring pattern with Johnson & Johnson’s earnings releases. The stock typically sells off when results are announced in the morning, then rebounds during the subsequent conference call. “If it gets blasted, try to get some,” he advised.
Diversification as a Core Strategy
Cramer’s overarching message centered on portfolio construction principles. He warned that concentrating exclusively in the market’s most popular names creates vulnerability because investor sentiment can pivot rapidly.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he said.
When specific market segments lose momentum, maintaining positions in undervalued securities ensures some holdings continue performing. Cramer attributed this wisdom to lessons learned during his time at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare equities have experienced significant pressure throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading sessions amid persistent sector-wide headwinds.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
